Mallinckrodt and Endo Merge in $6.7 Billion Deal: Implications for Manufacturing and Financial Strategy

One of the most significant effects of the merger will be the integration of both companies’ manufacturing capabilities. Mallinckrodt, historically known for its expertise in specialty branded and generic drugs, brings a portfolio that includes autoimmune treatments, pain management solutions, and ADHD medications. Endo, with a similar focus on pain management through brands like Percocet and Test